Combination Treatments and Uses and Methods Thereof
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsIra GUPTA, Axel HOOS
Life of this patent
Estimating the term…
Abstract
Disclosed herein are combinations of an antigen binding protein that binds BCMA with an antigen binding protein that bind to an immunomodulatory agent, such as PD-1, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combinations, including uses in cancer.
Claims23
A method of treating cancer in a patient in need thereof comprising administering an antigen binding protein that binds BCMA and an antigen binding protein that binds PD-1 comprising CDRH1 of SEQ. ID. NO:
- 11, CDRH2 of SEQ. ID. NO:
- 12, CDRH3 of SEQ. ID. NO:
- 13, CDRL1 of SEQ. ID. NO:
- 14, CDRL2 of SEQ. ID. NO:
- 15, and CDRL3:
- SEQ. ID. NO:
- 16, or variants thereof.
A method of treating cancer in a patient in need thereof comprising administering belantamab mafodotin and dostarlimab.
A method of treating multiple myeloma in a human in need thereof comprising administering on day 1 of a 21-day cycle (Q3W):
- a) about 0.95 mg/kg, about 1.9 mg/kg, about 2.5 mg/kg, or about 3.4 mg/kg of belantamab mafodotin, and
- b) about 500 mg of dostarlimab.
A combination comprising an antigen binding protein that binds to BCMA and an antigen binding protein that binds PD-1 comprising CDRH1 of SEQ. ID. NO:
- 11, CDRH2 of SEQ. ID. NO:
- 12, CDRH3 of SEQ. ID. NO:
- 13, CDRL1 of SEQ. ID. NO:
- 14, CDRL2 of SEQ. ID. NO:
- 15, and CDRL3:
- SEQ. ID. NO:
- 16, or variants thereof.
A combination comprising belantamab mafodotin and dostarlimab.
(canceled)
(canceled)
(canceled)
A kit comprising belantamab mafodotin and dostarlimab.
A method for treating a B cell disorder in a human, the method comprising (i) administering from about 0.95 mg/kg to about 3.4 mg/kg of belantamab mafodotin;
- and, (ii) administering 500 mg of dostarlimab.
Dependencies are inferred from the claim text.